论文部分内容阅读
目的 :评价特拉唑嗪、高特灵和哈乐三种α1受体阻滞剂治疗前列腺增生症的药物经济学。方法 :对 90例前列腺增生症病人分别应用特拉唑嗪、高特灵和哈乐进行治疗 ,运用药物经济学的费用 -疗效分析方法进行评估。结果 :三种药物治疗前列腺增生症疗效各有特点 ,均可明显改善前列腺增生症的主观和客观症状。结论 :特拉唑嗪为治疗前列腺增生症的较为经济且安全有效的口服药物
OBJECTIVE: To evaluate the pharmacology of terazosin, methotrexate, and halotile for the treatment of benign prostatic hyperplasia. Methods: 90 cases of benign prostatic hyperplasia patients were treated with terazosin, methotrexate and Harmony for treatment, the use of cost-effectiveness of pharmacoeconomics to assess the method. Results: The three drugs for the treatment of benign prostatic hyperplasia have their own characteristics and can significantly improve the subjective and objective symptoms of benign prostatic hyperplasia. Conclusion: Terazosin for the treatment of benign prostatic hyperplasia more economical and safe and effective oral drug